Background: Phenobarbitone is the most commonly used first-line drug for the treatment of neonatal seizures. A number of previous studies, with small subject numbers, have identified covariates that may influence the pharmacokinetics of phenobarbitone but results have been inconsistent. In particular, oral bioavailability is relatively poorly described and doses are commonly reported as being the […]
Author: Angela Williams
Pharmacokinetics of Phenobarbitone in Neonates – A Population Model Based on Routine Therapeutic Drug Monitoring Data
Background: Phenobarbitone is a commonly used first-line agent for treatment of neonatal seizures of varying causes. A significant proportion of neonatal seizures are due to Hypoxic-Ischaemic Encephalopathy (HIE). Babies with HIE who are treated with 72 hours of therapeutic hypothermia have an improved chance of survival without major disability. However, there is limited information regarding […]